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ABSTRACT 
CCR5 antagonists, such as Maraviroc (MVC) and 5P12-RANTES, are being evaluated as 
HIV preventatives. The advantage of these drugs is that they restrict HIV entry via CCR5 
receptor. However, sub-clinical concentrations could paradoxically increase HIV risk by 
increasing CCR5 expression. 
Peripheral blood mononuclear cells (PBMCs) and cervical tissues were cultured with one 
HIV antiretrovirals (ARVs), Maraviroc (MVC), 5P12-RANTES, dapivirine (DPV), or griffithsin 
(GRFT).  Immune cells isolated from PBMCs/cervical tissue were stained with live/dead stain 
and monoclonal antibodies. Samples were analyzed using a BD LSRII flow cytometer and 
FlowJo v. 10.1 software. To determine if suboptimal concentrations of antiretrovirals (ARVs) 
influence HIV susceptibility, PBMCs/cervical tissue were treated with MVC, 5P12-RANTES, 
DPV, or GRFT and challenged with HIV-1BaL.  Supernatant was collected on days 3, 7, and 11 
and then tested for viral p24 by the AlphaLISA.  
In PBMCs, 10 nM and 1nM MVC induced significant enhancement of CCR5+ 
expression levels when compared to DPV or GRFT treated cells, respectively. There were no 
significant changes in CCR5 MFI or percent positive cells found in the cervical tissue.  HIV 
replication, via p24 production, did not increase for any drug concentration in PBMCs, but 
975nM MVC significantly increased p24 expression in cervical tissue.   
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MVC is an effective therapeutic for HIV-infected persons, but may be problematic for 
HIV prevention due to its dose and time dependent qualities. Likewise, 5P12-RANTES showed 
similar trends in CCR5 expression. Topical application of CCR5 antagonists may be effective for 
only a short period in the genital tract. Conversely, DPV and GRFT did not affect CCR5 
expression. The use of CCR5 antagonists for HIV prevention should be reconsidered as other 
options become available.  The public health impact of improving topical HIV drugs could 
potentially reduce global HIV prevalence and shift toward an HIV-free world.   
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1.0  INTRODUCTION 
1.1 HUMAN IMMUNODEFICIENCY VIRUS 
1.1.1 Epidemiology  
In 2015, Human immunodeficiency virus (HIV) type 1 infected 36.7 million people 
globally, with 2.1 million new cases and 1.1 million deaths (1).  The HIV virus was originally 
transmitted to humans via a primate species in Africa, such as western lowland gorillas and 
mangabeys, through a mutation in simian immunodeficiency virus (SIV) (2, p574).  HIV was 
brought to the United States in the 1980’s where it caused wide-spread concern due to its unknown 
infection route and spread (3).  This disease predominately affected homosexual men that later in 
the disease progression developed rare, opportunistic infections with increased mortality from the 
general population (3).  In 1983, the first isolate was discovered in France and Bethesda, Maryland, 
which spearheaded the pursuit to classify the newly identified virus (4).  More than three decades 
following the discovery of HIV, rapid HIV detection techniques and preventative measures have 
been developed, but a successful vaccine is still absent (4).   Due to increasingly successful 
treatments, HIV rates have gradually declined since the 1997 peak of 3.7 million new cases that 
year, with currently more than 9.7 million people accessing antiretroviral therapy (ART) in low- 
or middle-income countries (5).  
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While HIV infects all corners of the globe, the most HIV-impacted region of the world is 
sub-Saharan Africa.  In 2000, 1.4 million people died from HIV-related illnesses, but by 2012 that 
number dropped to 1.2 million deaths and the HIV incidence was reduced by half (5).  This 
dramatic drop in HIV deaths and incidence is related to an increase in widespread ART access, 
even in remote locations (5).  The most common transmission route for HIV in Africa is 
unprotected, heterosexual intercourse, with an increased risk associated with multiple partners and 
other sexually transmitted infections, such as herpes simplex virus (5).  A majority of new HIV 
infections can be attributed to discordant couples, which make up two-thirds of the heterosexual 
couples in Africa, where females are more likely to be HIV+ than their male counterparts (5).  
Mother-to-child HIV transmission is another substantial risk factor in Africa, but access to ART 
has reduced mother-to-child transmission to less than 1% of live births and 860,000 infant HIV 
acquisitions avoided in 2012 (5). To further reduce HIV acquisitions in Africa, innovative HIV 
prevention strategies to further control disease transmission and acquisition are needed.     
1.1.2 Virology  
HIV has several routes of transmission: sexual contact, intravenous drug use, and 
perinatal transmission.  The virus is spread through contact with specific bodily fluids, such as 
blood, semen, vaginal/rectal secretions, and breast milk (6).  HIV causes a gradual decline CD4+ 
T cells and alterations in other immune cell levels such as macrophages, microglia, and dendritic 
cells, therefore reducing overall immunity of the individual.  Normal CD4+ counts range between 
500 to 1,500 cells/mm3, so when the virus depletes T cells to less than 200 CD4+ T cells/mm3 in 
circulation, HIV progresses to acquired immune deficiency syndrome (AIDS) (2, p573).   Low 
CD4+ T cells can make the body susceptible to opportunistic infections, such as Karposi 
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sarcoma, and eventually lead to death (2, p573).  HIV infects and replicates within activated 
immune cells such as CD4+ T cells, macrophages, and dendritic cells.  For CD4+ cells, the virus 
requires specific cellular surface proteins – CD4 in conjunction with CCR5 or CXCR4 – to gain 
entry (2, p576).  Once the virus enters the cell and establishes infection, it replicates using host 
cell machinery and newly formed virus spreads throughout the body (2, p.576-77).  HIV uses 
viral reverse transcriptase to convert viral RNA to complementary DNA (cDNA), which is 
ushered into the nucleus and the viral integrase incorporates the cDNA into the host DNA (2, 
p.576).  After integration, productive viral infection is established, where viral particles begin to 
assemble (2, p.576).  Viral proteins, including gp120 Env, are assembled at the cell membrane 
and bud from the infected cells to continue the spread of infection (2, p.576).  Upon budding 
from the infected cell, new viral particles can infect CD4+ T cells in the surrounding area and 
continue the HIV replication cycle.   
The gp120 binds to the CCR5 or CXCR4 receptor to facilitate HIV entry.  CCR5 (R5) 
tropic HIV viruses predominate early stages of infection, where CXCR4 tropic (X4) viruses arise 
over time (7).  Persons with a CCR5 delta32 mutation, a 32-base pair deletion in the CCR5 gene, 
can render the CCR5 binding site unusable to R5 tropic viruses (8).  The CCR5 gene deletion 
produces an abbreviated gene that does not produce a functioning CCR5 surface receptor (9).  
Delta32 homozygous individuals are resistant to R5 tropic HIV infection and delta32 
heterozygous individuals are categorized as ‘long-term progressors’ (9).  The primary mode of 
transmission worldwide is sexual contact through vaginal/penile or rectal/penile intercourse (10).  
While better access to treatment has reduced overall transmission, the lack of an effective 
vaccine still warrants research into other prevention options, such as blocking the sexual 
transmission route (10).    
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1.2 DRUGS AND TREATMENT 
1.2.1 Drug Classification 
There are several targets within the HIV replication cycle that are utilized as points for 
therapeutic interventions.  The HIV drug arsenal is comprised of: entry inhibitors, 
nucleoside/non-nucleoside reverse transcriptase inhibitors (NRTI/NNRTI), integrase inhibitors, 
and protease inhibitors.  These critical points have been exploited to create a combination 
treatment strategy comprised of three antiretroviral drugs, known as highly active antiretroviral 
therapy (HAART) which affects multiple points of the viral replication cycle (10).  Entry 
inhibitors block the virus’s ability to bind to surface receptors of the target cell (10).  The virus 
enters the cell by, using its glycoprotein 120 (gp120) trimer to bind with the CD4 receptor and a 
co-receptor, which consists of either CCR5 or CXCR4 (11).  Entry inhibitors target CCR5 
thereby preventing the binding viral gp120 or other molecules/residues such as carbohydrate 
moieties to block entry (11).   
NRTIs/NNRTIs interrupt the conversion of viral RNA to cDNA via HIV reverse 
transcriptase disruptions. NRTIs prevent the addition of nucleotides to the growing DNA chain 
during transcription, so HIV DNA synthesis is halted (10).  NNRTIs bind directly to the reverse 
transcriptase enzyme, inhibiting the conformational changes needed to elongate the DNA chain 
(10).  Integrase inhibitors prevent HIV cDNA from integrating into the target cell DNA by 
blocking the function of the HIV integrase enzyme (12).  The HIV integrase enzyme relocates 
viral cDNA into the target cell chromosome (13).  For retroviruses to replicate, the integrase 
enzyme ligates viral cDNA with host DNA (13).  Integrase inhibitors prevent the integration 
between host DNA and viral cDNA, so the replication cycle cannot be completed (13).  Finally, 
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protease inhibitors prevent viral assembly by interfering with HIV protease enzyme function 
(12).  HIV proteases cleave non-functional, structural polyproteins into functional proteins that 
the virus needs to mature the capsid (14).  In the presence of protease inhibitors, the virion 
particle cannot form a complete capsid, therefore halting viral replication (14).  These effective 
drugs have provided opportunities for use in HIV treatment and prevention. 
1.2.2 Maraviroc  
HIV CCR5-facilitated entry occurs at the initial stage of infection and more frequently 
than CXCR4-facilitated entry making the CCR5 receptor a prime target for drug development 
(15).  The oral formation of CCR5 entry inhibitor, Selzentry (Maraviroc) tablets, is FDA 
approved and recommended to be used in conjunction with other ARV drugs as second-line 
combination therapy.  Maraviroc (MVC) is well tolerated, safe, and effective at treating HIV 
with adjustable dosing to accommodate the needs of the patient (16).  MVC’s optimal 
effectiveness window for oral and topical MVC application varies by species and application 
time in relation to viral exposure.  The oral treatment is effective up to 4 hours post-
administration while topical application is most effective 0.5 hours after application but loses 
50% of its efficacy after 4 hours (15,17).  Timing the administration and application of MVC is 
crucial in preventing HIV infection; if the optimal effectiveness window is missed, HIV infection 
may occur.  MVC is effective via allosteric modification, which disrupts the interaction between 
the CCR5 receptor and gp120 surface HIV protein by the insertion of small MVC molecules (7).  
While MVC does not bind to the same structural component of CCR5 as HIV does, but it does 
prevent HIV entry by modifying the shape of the receptor and preventing proper HIV binding 
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(18).   In patients infected with X4 and duel tropic viruses, MVC presented little to no virologic 
advantage (7).     
Blocking the CCR5 receptor modifies the cytokines signaling by allosterically inhibiting 
agonist activation, indicating that MVC stabilizes CCR5 in an inactive conformation (19, 20).  
CCR5 is a co-activation molecule on the CD4+ T cell and can enhance T cell activation when 
accumulation occurs at the immunological synapse, but when CCR5 is blocked by entry 
inhibitors, like MVC, there is a decrease in CD4+ proliferation (21).   MVC has been shown to 
diminish in vitro chemotactic activity of T cells towards an assortment of cytokines, such as 
CCL3 and CCL5 (21).  The CD4+ T cells associated with CCR5 antagonists could inadvertently 
prevent T cells trafficking between circulation and the lymphatics through decreased cytokine 
activity (21).  High concentrations of MVC can reduce TNF-α, IFN-γ, and IL-4 in the 
supernatant and alter levels of chemoattractants CCL2 and CCL5 leading to suppression of T 
cell activation (19).  These two factors could reduce overall CD4+ T cell recruitment and chronic 
inflammation.  Due to its anti-inflammatory properties, MVC can be utilized to mitigate 
persistent inflammatory illness, such as certain cancers and autoimmune diseases (22).  
In the early stages of oral MVC efficacy and safety evaluations, MOTIVATE-1 and 2 
trials were conducted with R5 tropic infected individuals to determine the efficacy of one or two 
doses of oral MVC (7).  MOTIVATE-1 and 2 were randomized, double blind control trials, 
where oral MVC demonstrated a significant decrease in viral load and significant increase in 
CD4+ T cells up to 48 days after the initial MVC administration with two, 300mg doses of MVC 
daily (7).  The MOTIVATE trials demonstrated that long-term efficacy can be achieved with oral 
MVC by blocking the host protein with a small molecule antagonist, rather than only blocking 
the viral protein receptor (7).  While the oral formulation has proven effective, topical gel 
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formulations have been created for HIV prevention to halt infection at the mucosal membrane 
within the vaginal/colorectal tract.     
Topical application of MVC has demonstrated to be effective at preventing HIV 
transmission in mouse and macaque models, but has advantages and disadvantages with its 
formulation and effectiveness.  The topical CCR5 microbicides are geared toward prophylactic 
use at the mucosal site of infection, where a topical product is inserted vaginally or rectally directly 
preceding intercourse (17).  In a humanized mouse model, of the seven mice treated with topical 
MVC and exposed to HIV, none of the MVC-treated mice became infected compared to the 
placebo mice group after a 16-week treatment period (23). HIV DNA and RNA viral loads 
remained at undetectable levels (less than 102 copies/mL in plasma) over the 16-week period 
compared to all the placebo mice which had much higher plasma viral loads (more than 106 
copies/mL of plasma) (23).  Finally, the CD4+ counts remained constant in the MVC treatment 
mice post-HIV exposure, which was not seen in the placebo gel treated (23).  Rhesus macaque 
models were utilized to test if the gel formulation of MVC is equally as efficacious in a species 
that are comparable to humans.  The results mirrored the humanize mice results with similar 
concentrations of the drug; yielding complete protection at higher concentrations of MVC and an 
effective time frame between 0.5 to 4 hours post-application (18). 
1.2.3 5P12-RANTES 
In addition to MVC, 5P12-RANTES is a CCR5 entry inhibitor that prevents HIV infection 
and is being developed into a topical microbicide.  RANTES (CCL5) is a naturally occurring 
cytokine that attracts immune cells to the site of inflammation and regulates the immune response 
(24).  RANTES, along with MIP-1α and MIP-2β, can suppress HIV infection through binding the 
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CCR5 receptor with chemokines and blocking HIV gp120 binding (24).  The CCR5-blocking 
attributes along with its antigen independent T-cell activation makes RANTES an ideal candidate 
for an HIV entry inhibitor drug because immune cells will be recruited, but not susceptible to HIV 
infection (24).  RANTES binds to the CCR5 receptor leading to internalization of the 
receptor:ligand complex and removes the HIV entry target from the cells surface (25).  Hours after 
RANTES exposure, receptor cycling occurs, which allows more CCR5 receptors to appear on the 
surface of the CD4 cell, and the cell is vulnerable to infection once again (25).  Receptor cycling 
ceases after a few days, so an analogous long-acting RANTES drug was developed to mimic CCR5 
blockage without the inflammatory effects over several days (25).   5P12-RANTES is a large 
molecule entry inhibitor derived from the RANTES cytokine (24).  This HIV drug does not activate 
CCR5 and will therefore reduce unwanted inflammatory effects (24).  5P12-RANTES acts 
similarly to MVC; it binds to the CCR5 receptor and does not allow viral entry through CCR5 
binding and internalization (25). 
1.2.4 Dapivirine and Griffithsin  
To compare the effects of MVC and 5P12-RANTES, Dapivirine (DPV) and Griffithsin 
(GRFT) were used.  DPV is a small molecule NNRTI that demonstrated reduced HIV acquisition 
in women using an intravaginal ring containing the drug (26).  GRFT is a novel, 121 amino-acid 
carbohydrate-binding, protein entry inhibitor that is under consideration as treatment options for 
multiple diseases, such as Hepatitis C or Human Papillomavirus (27).  GRFT mechanism of action 
blocks infection by binding to the high mannose N-linked glycan portion of the viruses rendering 
them unable to enter the target cell (28).  This binding allows GRFT to be effective against CCR5 
and CXCR4-tropic HIV viruses (27).  GRFT is also stable at high temperatures and low pH, 
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making it an ideal compound for topical application in resource poor settings (27).  Both DPV and 
GRFT can be used as pre-exposure prophylaxis drugs (PrEP) and represent small molecule and 
protein controls for MVC and 5P12-RANTES respectively (26, 27). 
1.3 PUBLIC HEALTH SIGNIFICANCE  
HIV infects millions of people globally, costs billions of dollars in the healthcare industry, 
and leaves people with a life-long illness that eventually leads to death (1).  Making topical HIV 
drugs more effective and efficient for the most vulnerable populations would greatly improve HIV-
infected areas and reduce community viral loads.  The cost to formulate some of the drugs into pill 
or ring form can be inexpensive for people who truly need it.  For example, one 300mg MVC 
tablet, which costs about $15 in the US, can be made into a gel formulation that was shown to 
protect several macaques against SHIV infection (17), suggesting that this could be a feasible 
option for humans.  With rising HIV resistance, there is a need for innovative HIV drug 
development to combat this growing concern.  The more common second-line and PrEP drug 
usage becomes, the risk for drug resistance within the viral genome increases.  MVC drug 
resistance can occur when the gp120 mutates allowing for HIV binding despite the presence of the 
drug altering the receptor binding site (29).  Novel drug development, such as GRFT, should be a 
priority in the pharmaceutical industry to stay ahead of HIV mutations.  In certain parts of the 
world with a high HIV prevalence, taking pills or condom use to prevent HIV infection are 
stigmatized (30).  Therefore, other strategies, such as topical products, that are user controlled may 
increase uptake and use.     
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Topical HIV treatments can be used more discretely and have less stigma attached to them 
than a pill.  In Africa, disclosing a person’s HIV status has negative consequences, such as violence 
and infidelity accusations, and can lead to severe stigmatization within their community (30).  The 
potential for such stigma and the economic and social repercussions may cause an HIV-positive 
individual to forgo medication and treatment (30).  The use of a topical gel or vaginal ring is more 
discrete than traveling to a clinic to get daily HIV medication or requiring partners to wear 
condoms.  The topical gels can be applied without medical personnel and vaginal rings can last up 
to a month before needing replaced.  The independence associated with gels and rings can 
empower women to manage their lives and sexual health.  The continuing improvement of topical 
HIV products will further benefit public health globally by reducing the transmission and spread 
of HIV. 
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2.0  SPECIFIC AIMS 
2.1 PROJECT STATEMENT 
While CCR5 antagonists appear to be effective for treatment, their use for HIV 
prevention may raise some public health concerns.  CCR5 antagonists, such as MVC, prevent 
natural binding of CCR5 receptor:ligand complex reducing internalization (31).  The lack of the 
complex internalization leads to an increase in surface CCR5 and circulating CCR5 ligand (31).  
Because MVC has such a short half-life in the genital tract, the effects of sub-clinical 
concentrations of MVC on the immune cell population within the genital mucosa should be 
explored for alterations in CCR5 expression (17).  For this study, we hypothesize that sub-
clinical concentrations of MVC and/or 5P12-RANTES could paradoxically increase HIV risk by 
increasing CCR5 expression on the surface of target cells.  More CCR5 receptors would make 
target cells more susceptible to HIV infection and exacerbate the spread of HIV in already high 
risk areas.    
2.2 PROJECT SPECIFIC AIMS 
Specific Aim 1 
Examine the effect of sub-clinical concentrations of MVC, 5P12-RANTES, DPV, or GRFT 
will have on CCR5 surface receptor expression.  PBMCs and immune cells isolated from cervical 
tissue will be analyzed through flow cytometry to quantify surface CCR5 expression on individual 
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cells and the number of CCR5 positive cells within a lymphocyte population, through mean 
fluorescence intensity (MFI) and percent positive metrics.  An increase in CCR5 positive cells and 
number of CCR5 receptors could increase the likelihood of HIV infection within vulnerable 
populations. 
Specific Aim 2   
Examine the effect of sub-clinical concentrations of MVC, 5P12-RANTES, DPV, and 
GRFT will have on HIV infectivity and replication.  PBMCs and immune cells isolated from 
cervical tissue will be infected with HIV and treated with an HIV drug, then a structural p24 protein 
analysis, p24 AlphaLISA, will be performed to quantify HIV replication within CD4+ cells. An 
increase in p24 expression is a result of increasing HIV infection in target cells that could cause 
HIV to spread.     
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3.0  METHODS 
3.1 REAGENTS  
The HIV strain used was the laboratory strain HIV-1BaL.  The reagents used for flow 
cytometry included: near-IR live-dead (Molecular Probes, Eugene, OR), CCR5 (BV421, clone 
3A9), CD69 (PE, clone FN50), CD45 (PerCP-Cy5.5, clone HI30), CD4 (BB515, clone RPA-T4), 
CD8 (BV510, clone SK1), and CD3 (APC, clone UCHT1) monoclonal antibodies (BD 
Biosciences, San Diego, CA).  Optimal antibody concentration was determined through antibody 
titrations to ensure the brightest signal with the lowest background noise.    
3.2 PBMC FLOW CYTOMETRY ASSAY 
Buffy coats were obtained from healthy donors at the Central Blood Bank.  PBMCs were 
isolated from buffy coats using Ficoll-sodium metrizoate separation gradient.  The PBMCs were 
treated with the indicated concentrations of MVC, DPV, GRFT, or 5P12-RANTES for 48 hours 
in 5% CO2 /37°C.  After treatment, PBMCs were washed and adjusted to 1×106 cells per mL in 
PBS and stained with near-IR live-dead viability dye for 25 minutes protected from light at room 
temperature.  The cells were then washed and stained with the following antibodies in order: 
CCR5 (BV421, clone 3A9), CD69 (PE, clone FN50), CD45 (PerCP-Cy5.5, clone HI30), CD3 
(APC, clone UCHT1), CD4 (BB515, clone RPA-T4), and CD8 (BV510, clone SK1).  The cells 
were incubated for 25 minutes protected from light at room temperature.  Cells were washed and 
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fixed with 1× red blood cell lysis buffer (Roche, Basel, Switzerland).  The fixed cells were 
suspended in FACS buffer (BD Bioscience) and analyzed using BD LSR II Flow Cytometer (BD 
Bioscience) (32).  Fluorescent minus one (FMO) and isotype controls were utilized to determine 
proper gate placement and spectral overlap was accounted for by single color compensation 
controls.  Cells were gated on singlet, live lymphocytes (Figure 1).  Live, CD45+ cells were gated 
from the single cells to further analyze the CD4+ cell population expressing CD69 and CCR5.  
MFI and percent positive metrics were collected.  
 
 
Figure 1.  Flow cytometry gating strategy.  
 
The analysis template was used for PBMCs and immune cells isolated from cervical tissue.  The flow cytometry 
data was analyzed using FACS Diva v6.2 (BD Bioscience) and FlowJo v.10 software (Tree Star Inc., Ashland, OR). 
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3.3 CERVICAL TISSUE FLOW CYTOMETRY ASSAY 
The cervical and colorectal tissues were obtained through the University of Pittsburgh 
Health Sciences Tissue Bank (Pittsburgh, PA) under IRB-approved protocols (IRB 
PRO09110431), or procured from tissue donated to the National Disease Research Interchange 
(NRDI, Philadelphia, PA).  Tissue pieces were divided into four treatment groups: negative 
control, positive control, MVC versus DPV or 5P12-RANTES versus GRFT.  Each group 
contained 4-6 pieces of tissue which was approximately 500mg.  After treatment, tissues were 
minced using sterile scissors and digested in 20mL RPMI containing 1% Collagenase B (Roche) 
and 0.5% DNAse (ThermoFisher, Waltham, MA). After digestion, samples were filtered through 
a 40μm cell sieve to generate a single-cell suspension (Becton Dickenson, Franklin Lakes, NJ). 
The isolated mucosal immune cells were stained for flow cytometry following the same 
procedure used for PBMCs.  
3.4 HIV INFECTION OF PBMCS AND CERVICAL TISSUE ASSAY 
Isolated PBMCs were treated with MVC, DPV, 5P12-RANTES, or GRFT for 48 hours in 
a 96-well plate at 5% CO2 and 37°C.   After 48 hours, the samples were washed with media to 
remove the drug then 5×103 or 5×102 tissue culture infectious dose for 50% infectivity (TCID50) 
of HIV-1BaL was added to the appropriate wells.  After 3 hours, the virus was washed with media 
and incubated for 7 days.  On days 3 and 7, 100μL of supernatant was removed and frozen at -
80°C until a high sensitivity AlphaLISA p24 ELISA (Perkin Elmer, Bridgeville, PA) was 
performed.  Previously collected and analyzed AlphaLISA p24 data for HIV-infected cervical 
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tissue was used for statistical analysis in determining HIV replication in MVC, DPV, GRFT, and 
5P12-RANTES treated cervical tissue (33, unpublished data). 
3.5 STATISTICAL ANALYSIS 
One-way ANOVA was used to compare relationship between drug concentrations and 
CCR5+CD4+ percent positive and MFI.  Dunnett’s post hoc analysis was used to compare the 
negative control to drug treatment groups. Both tests were measured at a level of α=0.05. 
Graphpad Prism 7 software (Graphpad Software Inc., La Jolla, CA) was used to statistically 
analyze the data and generate graphical representations of the data.  For the HIV-infected PBMC 
analysis, a one-way ANOVA was used for compare the combined day 3 and 7 p24 levels of the 
various treatment groups using Prism 7.  Previously collected AlphaLISA p24 cervical tissue 
data was statistically analyzed comparing MVC, DPV, GRFT, and 5P12-RANTES drug dilutions 
to an HIV control (33, unpublished data).  For the HIV-infected tissue, the two p24 replicates 
from day10/11 of the AlphaLISA were averaged and entered into Stata14 software (StataCorp 
LP, College Station, TX).  A linear or quadratic correlation between the data was established.  If 
there was a linear correlation, the data were analyzed with a generalized estimating equation 
(GEE) linear model.  If there was a quadratic correlation, the data were analyzed with a GEE 
non-correlated model.  
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4.0  RESULTS  
4.1 PBMC FLOW CYTOMETRY DEMONSTRATE INCREASE CCR5 
EXPRESSION WITH MVC  
To determine whether CCR5 antagonists affect cellular expression of CCR5, two CCR5 
antagonists, one a small molecule (MVC) and other a large protein (5P12-RANTES), were 
compared to other HIV prevention compounds, DPV and GRFT, which reflects a small molecule 
and large protein as controls.  In PBMCs, there were significant differences in the mean 
fluorescence intensity (MFI) between the untreated controls and those treated with MVC, the 
1µM and 10nM dose (p = 0.006 and p=0.0231, respectively) (Figure 3A).  There were 
statistically significant differences between the DPV, 5P12 RANTES, or GRFT treatments, but 
5P12 RANTES MFI expression mirrored that of MVC.  For DPV, 5P12 RANTES, and GRFT no 
concentrations exhibited a significant percent positive cells or MFI difference from the negative 
controls (Figure 2A-2D or 3A-3D).  The changes in percent positive cells were not significant for 
1µM or 10nM MVC, but there were several replicates with higher concentrations of CCR5+ 
cells.  5P12-RANTES showed a similar trend in that both concentrations (10nM and 1nM) had 
higher expression of CCR5 (percent positive cells and MFI; Figure 2C and 3C) and a dose 
response was noted, but these differences did not reach statistical significance.   While the 
change in CCR5 was not statistically significant, there was a 2 to 3.6-fold increase in CCR5 
expression after culture with 5P12-RANTES and MVC, respectively (Table 1).   
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Figure 2.  Percent positive cells from flow cytometry analysis of drug-treated PBMCs. 
 
Expression of CCR5 on CD4+ cells treated with Maraviroc (MVC; A), Dapivirine (DPV; B), 5P12-RANTES (C), 
and Griffithsin (GRFT; D) for 48 hours.  Total lymphocytes were gated on the live CD4+CD8- cells (n=5 buffy 
coats.  Horizontal bars represent mean ± standard deviation (SD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
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Figure 3.  Mean fluorescence intensity from flow cytometry analysis of drug-treated PBMCs. 
 
Expression of CCR5 on CD4+ cells treated with Maraviroc (MVC; A), Dapivirine (DPV; B), 5P12-RANTES (C), 
and Griffithsin (GRFT; D) for 48 hours. Total lymphocytes were gated on the live CD4+ CD8- cells (n=5 buffy 
coats).  ** p=0.006; * p=0.0231.  Horizontal bars represent mean ± standard deviation (SD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Table 1.  MFI characteristics of drug-treated PBMCs  
 
 
  
 
 
 
4.2 CERVICAL FLOW CYTOMETRY DEMONSTRATED NO SIGNIFICANT 
CHANGE IN CCR5 EXPRESSION 
Isolated immune cells from cervical tissue were treated with MVC or DPV.  The treated 
tissue did not show a significant increase in either CD4+CCR5 percent positive cells or MFI 
(Figure 4A & 4C).  For 5P12-RANTES or GRFT, there was no significant increase of CCR5 
expression, percent positive cells or MFI, on CD4+CCR5 cells (Figure 4B & 4D).  At the 
concentrations tested, MVC was the only drug that demonstrated any increase in CCR5 
expression compared to the negative control (Table 2).   
Treatment CCR5 MFI change 
Fold change 
from negative 
control  
DPV 1uM 457.52 0.745 
DPV 10nM  1498.76 2.442 
Maraviroc 1uM 2253.7 3.673 
Maraviroc 10nM  2029.58 3.307 
Negative control 613.64 - 
   
GRFT 1nM 1511.2 1.238 
GRFT 100pM  1440.2 1.180 
GRFT 10pM  1037.56 0.850 
GRFT 1pM  1702.96 1.395 
5P12-RANTES 10nM 2357.38 1.931 
5P12-RANTES 1nM 2272.88 1.862 
5P12-RANTES 100pM 1849 1.515 
5P12-RANTES 10pM 1430.54 1.172 
Negative control 1220.6 - 
CCR5 measurements in PBMCs for MVC, DPV, GRFT, or 5P12-RANTES compared to the negative 
control (n=5). 
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Figure 4.  Flow cytometry analysis of isolated immune cells from cervical tissue. 
 
Isolated immune cells from 5 independent cervical tissues treated with MVC, DPV, GRFT, or 5P12-
RANTES and analyzed by flow cytometry (n=5).  No significant changes in CCR5 expression, percent positive cells 
or MFI, for any drug concentration of MVC/DPV (A and C) or GRFT/5P12-RANTES (B and D) was noted.  
Horizontal bars represent mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Table 2.  MFI characteristics of isolated immune cells from cervical tissue. 
 
Treatment CCR5 MFI change 
Fold change 
compared to 
negative 
control 
DPV 1uM 3573.24 0.951 
 Maraviroc 1uM 4783.84 1.273 
Negative control 3758.22 - 
   
GRFT 1nM 2966.03 0.870 
5P12-RANTES 10nM 3287.62 0.965 
Negative control 3407.52 - 
 
4.3 PBMC P24 ALPHALISA DEMOSTRATES HIV SUPPRESSION WITH GRFT  
To determine if the increase in CCR5 resulted in enhanced HIV infection, PBMCs were 
treated with several concentrations of MVC, DPV, GRFT, or 5P12-RANTES, washed and then 
exposed to HIV.  For HIV 5×103 and 5×102 TCID50, DPV and MVC suppressed HIV infection at 
10nM and 1nM, but suppression was not significant (Figure 5A & 5C).  For 1nM GRFT and 
10nM 5P12-RANTES, there was significant suppression at the 5×103 TCID50 (p=0.0199 and 
p=0.0308, respectively) (Figure 5B).  No significant increase or decrease in p24 expression at 
100pM GRFT or 1nM 5P12-RANTES (Figure 5B).  The 5×102 TCID50 had poor viral replication 
for both MVC/DPV and GRFT/5P-12 (Figure 5C & 5D).  
CCR5 in isolated immune cells from cervical tissue for MVC, DPV, GRFT, or 5P12-RANTES (n=5)  
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Figure 5.  p24 analysis of drug-treated PBMCs. 
 
Day 3 and day 7 cumulative, median p24 values for five PBMC donors.  HIV-1BaL is the untreated control.  
MVC/DPV (A and C) showed no significant increase or suppression of p24 expression.  GRFT (1nM) and 5P12 
RANTES (10nM) significantly decreased p24 expression (B). ** p=0.0199; * p=0.0308.  The data represents 
treatment of five independent blood donors and tested in duplicate.  Horizontal bars represent mean ± SD.   
A 
D 
B 
C 
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4.4 CERVICAL P24 ALPHALISA DEMONSTRATES INCREASE HIV 
REPLICATION WITH MVC 
Cervical tissue treated p24 data with varying drug concentrations of DPV or MVC (33) 
and GRFT or 5P12-RANTES (unpublished data) were evaluated for efficacy against HIV 
infection.  These data were used here to determine if the suboptimal dose of drug influence HIV 
infection as reflected by the viral p24 quantification.  GEE analysis was used to evaluate the 
average p24 response at day 10/11 among the control and treatment groups and to determine if 
the p24 expression was dose dependent.  The p24 expression was higher in the 97.5nM MVC-
treated tissue as compared to the HIV control, but the increase was not significant (Figure 6A).  
The 975nM MVC-treated tissues showed significantly increased p24 expression above the HIV-
1BaL control p24 levels (p=0.025), while higher MVC concentrations significantly suppressed 
p24 expression at day 10/11 (Figure 6A).  DPV at 79.5nM showed a significant increase in p24 
expression above the HIV control levels (p = 0.007; Figure 6B); however, four tissues were used 
in this experiment which may have influenced the results.  All concentrations of DPV greater 
than 759nM significantly suppressed p24 expression (Figure 6B).  All concentrations of 5P12-
RANTES and GRFT significantly suppressed HIV replication in cervical tissue (Figure 6C & 
6D).  
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Figure 6.  p24 analysis of isolated immune cells from cervical tissue. 
 
MVC (A), DPV (B), GRFT (C), or 5P12-RANTES (D) treated cervical tissue was analyzed for HIV-1 p24 
expression (n=5). MVC 975nM significantly increased p24 expression (5A, p=0.025).  Horizontal bar represents the 
median.  Five independent cervical tissues tested in duplicate. 
 
D 
A B 
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5.0  DISCUSSION 
Different categories of HIV drugs target multiple sites of the viral replication cycle to halt 
the virus replication at different points.  The first line of defense in preventing infection is the 
entry inhibitor class of drugs, such as MVC, 5P12-RANTES or GRFT (10).  These drugs block 
the viral gp120 surface protein from binding to its respective co-receptor, through either CCR5 
or CXCR4 (10).  The next drug categories are non-NRTIs/NNRTIs, such as DPV (10).  These 
drugs prevent viral RNA from being converted to DNA, which would then be integrated into the 
host genome (10).  Once in the nucleus of the host cell, integrase inhibitors are used to prevent 
integrating the newly converted viral cDNA into the host genome (13).  If the virus manages to 
surpass all those antiretroviral road blocks, then protease inhibitors can prevent viral assembly at 
the very last stage of viral replication (12).  These drugs prevent the virus from maturing and 
exiting the host cell to infect more cells (12).   
CCR5 entry inhibitors were at the forefront of this study, examining whether sub-clinical 
concentrations of entry inhibitor drugs could alter CCR5 expression (31).  The CCR5 entry 
inhibitors had some impact on CCR5 receptors in PBMCs and immune cells in cervical tissue.  
In the PBMCs, MVC increased the number of CCR5 receptors on the surface of CD4+ T cells as 
demonstrated with CCR5 MFI increases, but MVC did not have an impact on the number of cells 
expressing CCR5+.  While there were similar trends, the other entry inhibitor, 5P12-RANTES, 
did not significantly alter the number of percent positive cells or the number of surface CCR5 
receptors.  The other drugs used here, DPV and GRFT, did not have any significant impact on 
the number of percent positive or surface CCR5.  Interestingly, little change in CCR5 expression 
or numbers of positive cells was found after culturing cervical tissue with sub-optimal 
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concentrations of the drugs tested.  It is not clear why similar findings were not found between 
the PBMCs and the immune cells from cervical tissue.  However, additional time points after 
treatment should be considered as 48 hours may have been too soon after treatment to quantify 
changes in CCR5 expression in intact tissue.  Moreover, higher concentrations of the drugs could 
be considered for testing as we have shown more drug is needed in the tissue models compared 
to the in vitro models (34).      
In HIV-infected PBMCS, none of the drugs caused a significant increase in HIV 
infection, even at sub-optimal concentrations of drug.  The higher concentrations of 5P12-
RANTES and GRFT, 10nM and 1nM respectively, had a significant protective effect on 
PBMCS.  In the cervical mucosa, the number of CCR5+ cells and the number of CCR5 receptors 
on the cell surface were consistent with the negative control amounts across all drug treatment 
groups.  The HIV p24 expression in cervical tissue significantly increased for the lowest 
concentration of MVC (97.5nM) at day 11 of infection.  The lowest concentration of DPV 
(75.9nM) also significantly increased in p24 expression, but that treatment had fewer cervical 
tissues tested, which could have impacted our findings.  All other concentrations of DPV, GRFT, 
and 5P12-RANTES exhibited significant HIV protective effects in cervical tissue.  The other 
concentrations had significantly lower p24 values than the HIV control, which demonstrates the 
drugs are preventing HIV infection in cervical mucosa.   
Subclinical concentrations of MVC caused an increase of surface CCR5 receptors of 
PBMCs and increased p24 immune cells from cervical tissue.  The concentrations evaluated of 
MVC affected peripheral and mucosal CD4+ T cells differently leading to antiviral activity in 
PBMCs but not cervical tissue (12).  For peripheral CD4 T cells, complete HIV protection was 
achieved at a lower concentration and shorter exposure time in the presence of MVC; however, 
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this result was not mimicked in mucosal immune cells (12).  Immune cells isolated from cervical 
tissue did not achieve complete HIV protection, despite the prolonged and constant drug 
exposure (12).   The CCR5 receptor is a dynamic modulated G-protein-coupled receptor, which 
can be expressed differently at various stages of activation, so the gp120 binding to CCR5 is 
affected by the co-receptor conformational state (12).  Contrary to the tissue-specific CCR5 
response, MVC has been found effective in PBMCs at concentrations as low as 47.2nM (35).  
The variance in drug efficacy between PBMCs and cervical immune cells could be attributed to 
sample drug exposure. PBMC T cells are more readily exposed to MVC than resident immune 
cells within the tissue.  MVC needs to penetrate into the tissue to reach its target cells, which 
could alter the effective concentration when compared to PBMCs.  MVC is a small molecule 
HIV drug and there is an inverse relationship between drug molecule size and drug penetrating 
abilities (36).  The larger molecules, 5P12-RANTES and GRFT, cannot diffuse across the 
mucosal membrane to the target cells.   In PBMCs, penetrating qualities are not necessary 
because the target CD4 cells are in single-cell suspension making CCR5 binding readily 
available.  Molecular penetration could account for the disparity in the PBMC and cervical tissue 
data. 
In more recent findings, MVC has not demonstrated effective HIV prevention as was 
once thought.  The HIV Prevention Trials Network (HPTN) 069 study is a phase two study 
comparing oral MVC alone with two different combination therapies, MVC + emtricitabine 
(FTC) or MVC + tenofovir disoproxil fumarate (TDF), to be used as PrEP for men who have sex 
with men (MSM) in the United States (37).  The study yielded contrasting results from what has 
been demonstrated in animal models.  Over the course of the study, five participants acquired a 
R5 tropic HIV infection, four of them where in the MVC only group (4.5% of MVC-only study 
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arm) (37).  Two of those five participants had no detectable MVC in measured plasma levels and 
two more has suboptimal plasma concentrations at the time of seroconversion (37).  Previous 
PrEP MVC efficacy studies have shown varying levels of success between animal models.  The 
results from this study contradict results from Neff et al that demonstrated HIV prevention using 
oral MVC in humanized mouse models with HIV vaginal challenge (23).  In macaque models, 
Massud et al found that one MVC dose 24 hours prior to rectal viral challenge resulted in five of 
the six macaques acquiring simian/human immunodeficiency virus (SHIV) (38).  Sufficient drug 
concentration sustainability within the mucosal tissue should also be considered when 
determining PrEP formulations.  Veazy et al demonstrated effective SIV prevention with topical 
MVC in macaques, but the sample size was small and the drug doses administered were above 
the recommended clinical dosing (17).  While oral PrEP regimens may differ compared to 
topical regiments, the lack of efficacy demonstrated by Gulick et al should be considered when 
moving forward with MVC as a PrEP option (37).                   
 There were several limitations associated with this project that will need additional 
research to confirm the findings.  The tissues were obtained from women undergoing surgery 
and may have had hormone or chemotherapy treatments leading up to the surgery date.  The 
resections are typically obtained from older women, 35 years of age and older, and may not be 
generalizable to younger women.  Limited information was provided from the blood bank with 
the buffy coats.  Gender and ages of blood donors were not identified unless that information 
was specifically requested from the blood bank.  
To understand the effect of MVC and 5P12-RANTES may have on RANTES production 
from treated PBMCs and immune cells isolated from cervical tissue, multiplex ELISA analysis 
can be used to capture and determine how much RANTES (CCL5) is being expressed in HIV 
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infected and drug treated CD4+ cells.  Combining the amount of RANTES produced with the 
quantified number of CCR5 receptors through flow cytometry, future studies may be able to 
determine CCR5 internalization and cycling on the target cell surface.  A better understanding of 
this process could be used to determine which sub-optimal drug concentrations could result in 
increased risk of infection.  Cell migration assays can also be used to determine the chemotactic 
effects of altering CCR5 surface expression.  Higher drug concentrations should be explored 
with cervical tissue with a short dosing period to determine if these exposures lead to CCR5 
modulation.  
Further development of topical HIV prevention drugs may improve the quality of care for 
many people, especially in resource-poor areas.  The data provided here suggest subtle 
alterations of CCR5 could occur with CCR5 antagonist drugs.  Other entry inhibitor drug classes, 
such as GRFT, may be a better option for future topical microbicide development.  Giving 
women safe, effective, and alternative options for HIV prevention will hopefully empower 
women and reduce stigmatization within their communities.  Improving HIV drug treatment and 
management is leading us one step closer to creating an AIDS-free generation.   
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APPENDIX : SUPPLEMENTAL FIGURES 
 
Supplemental Figure 1.  Example histogram of MVC or DPV treated PBMCs. 
 
Supplemental Figure 2.  Example histogram of MVC or DPV treated immune cells isolated from cervical tissue. 
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